Serogroup C meningococcal conjugate vaccines generally use diphtheria or tetanus toxoids as the protein carriers. The use of alternative carrier proteins may allow multivalent conjugate vaccines to be formulated into a single injection and circumvent potential problems of immune suppression in primed individuals. Bordetella pertussis fimbriae were assessed as carrier proteins for Neisseria meningitidis serogroup C polysaccharide. Fimbriae were conjugated to the polysaccharide using modifications of published methods and characterised by size exclusion chromatography; co-elution of protein and polysaccharide moieties confirmed conjugation. The conjugates elicited boostable IgG responses to fimbriae and serogroup C polysaccharide in mice, and IgG:IgM ratios indicated that the responses were thymus-dependent. High bactericidal antibody titres against a serogroup C strain of N. meningitidis were also observed. In a mouse infection model, the conjugate vaccine protected against lethal infection with N. meningitidis. Therefore, B. pertussis fimbriae are effective carrier proteins for meningococcal serogroup C polysaccharide and could produce a vaccine to protect against meningococcal disease and to augment protection against pertussis. ß
Introduction
The capsular polysaccharide constitutes a major virulence factor of many pathogenic bacteria that cause invasive disease, including Neisseria meningitidis. Antibodies to the capsular polysaccharide of serogroup C N. meningitidis are protective and bactericidal [1^3] . Polysaccharides are thymus-independent (TI) antigens because they do not require mature T-cells to elicit a humoral response in vivo. However, whilst polysaccharide antigens are immunogenic in adults, they are only poorly or non-immunogenic in infants and young children, who are highly susceptible to infection caused by encapsulated bacteria [4] . In addition, TI antigens generally fail to elicit a memory response or a¤nity maturation. In contrast, the ability to respond to thymus-dependent antigens (TD), which is present at birth, results in the formation of memory cells; the antibody response subsequently undergoes a¤nity maturation following boosting [5] . For TI antigens, IgG3 and IgM are the major antibody isotypes expressed in mice, even after secondary immunisation. In contrast, for TD antigens, the ratio of IgG to IgM increases after boosting, with IgG1 being the major subclass in mice [6] .
Polysaccharide antigens, or hydrolysed fragments of these polysaccharides, can be converted to TD antigens by conjugation to a protein carrier. The Haemophilus in£uenzae type b capsular polysaccharide conjugate vaccine has been successfully introduced in many national childhood vaccination programmes [7] . N. meningitidis serogroup C polysaccharide conjugate vaccines have now been developed. Clinical trials for these vaccines proved successful [8] and, as a consequence, a number of these vaccines were introduced into the UK vaccination schedules in 1999. These conjugate vaccines have already had a signi¢cant impact on the incidence of disease in immunised groups [9] . However, these vaccines use either diphtheria or tetanus toxoids (DT and TT respectively) as the protein carrier [10^13] which does not broaden protection as these proteins are components of other vaccines, and infants may have maternal antibody to these proteins.
While the combination of puri¢ed capsular polysaccharide vaccines does not generally alter the immunogenicity of the individual polysaccharides, a reduced response to the polysaccharide moiety of individual conjugates has been observed when administered in multivalent formulations. In addition, where mice have been pre-primed with the carrier protein, a reduction in antibody responses has been observed [14] . This indicated that epitopic load rather than the antigenic load at the site of injection resulted in reduced immunity to conjugates. In addition, individual components of multivalent capsular polysaccharide vaccines conjugated to the same carrier proteins could compete for a limited number of speci¢c carrier proteinprimed T cells. Therefore, the development and use of multiple carrier proteins should be considered as an approach to reduce interference when more than one conjugate vaccine is used, especially if they are to be formulated into a single injection.
In this study, Bordetella pertussis ¢mbriae were assessed as carrier proteins for the capsular polysaccharide of N. meningitidis serogroup C. Although these proteins are not components of some acellular pertussis vaccines, recent clinical trials have shown that ¢mbriae are important protective antigens against whooping cough [15] . Use of B. pertussis ¢mbriae as protein carriers could, therefore, produce a vaccine that would protect against meningococcal disease and also augment protection against whooping cough where acellular vaccines de¢cient in ¢mbriae are used. It would also introduce an alternative carrier to DT and TT in conjugate vaccines and be potentially useful as a carrier in other conjugate vaccines, such as Hib [16] and pneumococcal vaccines, and would be an advantage if more than one vaccine were to be used or given as multivalent formulations.
Materials and methods

Puri¢cation of antigens
Fimbriae (a mixture of ¢m2 and ¢m3) were puri¢ed from B. pertussis strain Wellcome 28 using the method of Robinson et al. [17] , and meningococcal serogroup C polysaccharide (menCPs) was puri¢ed in-house from N. meningitidis strain L91 543 (C:2a:P1.2R) using standard methodology [18] . The molecular masses of puri¢ed ¢mbriae and menCPs were estimated by size exclusion chromatography (SEC) using a Hiload Superdex 200 HR (16/60) column (Amersham Pharmacia). The void volume (V 0 ) was determined using Blue dextran and the column calibrated for proteins using a gel ¢ltration molecular weight calibration kit (Amersham Pharmacia). The column was calibrated for polysaccharides using Polysaccharide SAC-10 dextran standards (Polymer Laboratories, Shropshire, UK). The apparent molecular masses of native ¢mbriae and menCPs were s 400 000 Da as both eluted in the void volume (V 0 ) of the column.
Dissociation of ¢mbriae
Native ¢mbriae in 0.5 M phosphate bu¡er, pH 7.2, were precipitated by the addition of 2 vols. of ice-cold acetone. The precipitate was recovered by centrifugation in a bench centrifuge at 4000 rpm for 20 min. The acetone was allowed to evaporate from the pellet, which was then resuspended in 6 M guanidine HCl (Gdn HCl), 0.125 M ethanolamine, pH 10.5, and allowed to equilibrate overnight at 4³C to dissociate the ¢mbriae [19] . The dissociated ¢mbriae (dFim) were dialysed against at least three changes of 0.1 M ammonium bicarbonate, pH 7.2, and concentrated by freeze-drying prior to conjugation [16] . SEC (Section 2.1) of dFim gave a molecular mass of approx. 25 000 Da, indicating dissociation into ¢mbral subunits which have estimated molecular masses of 22 500 Da (¢m2) and 22 000 (¢m3) [19] .
Preparation of conjugates
Dissociated ¢mbriae (dFim) were conjugated to menCPs using carbodiimide-mediated coupling [20] or reductive amination [21, 22] , producing the conjugates dFim-menCPs(EDC) and dFim-menCPs(RA), respectively.
Carbodiimide coupling
Carbodiimide coupling involved derivatising dFim using adipic acid dihydrazide (ADH) as a C 6 spacer and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl (EDAC), facilitating coupling of the amino group of ADH to cyanogen bromide-activated menCPs. Brie£y, ADH derivatives of proteins were prepared by reacting protein solutions (1 mg ml 31 ) and ADH (3.45 mg per mg protein) with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl (EDAC) (0.3 mg per mg protein). The reaction mixture was maintained at pH 4.7 þ 0.2 by careful addition of 0.1 M HCl on ice. The reaction was allowed to proceed at room temperature for 3 h and terminated by dialysing (MW cuto¡ 12 000; Sigma) at 3^8³C against at least three changes of 5 l of 20 mM ammonium bicarbonate, pH 7.2. The protein derivatives were then freeze-dried.
To activate menCPs with cyanogen bromide (CNBr), a solution of menCPs (45 mg ml 31 ) was equilibrated on ice, in 250 mM Na 2 CO 3 , pH 10.5. CNBr (500 mg ml 31 in acetonitrile) was added to a ¢nal concentration of 0.4 mg per mg polysaccharide and the pH maintained at 10.5 for 6 min. The reaction mixture pH was then lowered to pH 8.5 by careful addition of 1 M HCl. The derivatised ADH-protein was added to the CNBr-activated menCPs at a protein:polysaccharide molar ratio of 1:10. The reaction mixture was mixed gently overnight at 3^8³C, after which time the mixture was dialysed (MW cuto¡ 12 000; Sigma) against at least three changes of 5 l of 50 mM ammonium bicarbonate, 150 mM NaCl, pH 7.2, to remove hydrolysed, unconjugated polysaccharide before freeze-drying and puri¢cation by size exclusion chromatography. The conjugate was puri¢ed using a Hiload Superdex 200 HR (16/60) column (Amersham Pharmacia); the conjugate eluted in the void volume (V 0 ). Protein was detected by absorbance at 280 nm and polysaccharide was detected by changes in refractive index (RI) using an RI detector (Viscotek) [23] . Co-elution of protein and polysaccharide in V 0 con¢rmed conjugation. The concentrations of protein and polysaccharide were determined using the appropriate assays (Sections 2.4 and 2.5).
Reductive amination
To couple spaced, surface lysines to dFim [21] , protein (10 mg dFim) was dissolved in 9 ml of 50 mM HEPES, pH 8.5 (1.1 mg ml 31 ), in a glass bottle, to which 225 Wl of lysine solution (2 mg ml 31 ) was added, followed by 1 ml dimethyl suberimidate-2 HCl (DMS, 25 mg ml 31 ). The solution was mixed for 1 h at room temperature before adding a further 2 ml of the lysine solution to stop the reaction. The material was dialysed (MW cuto¡ 12 000; Sigma) overnight against at least three changes of 5 l of 0.1 M PBS, pH 7.4. The dialysed derivatised protein was then concentrated at 25³C using polyethylene glycol (PEG, 8000 Da molecular mass) until the volume was reduced to 1^2 ml. The concentrate was then dialysed (MW cuto¡ 12 000, Sigma) against at least three changes of 5 l of 100 mM sodium bicarbonate, pH 9.0, overnight at 4³C.
Polysaccharide was used at a molar ratio (protein :polysaccharide) of 1:10, based on the number of moles of starting material. Oxidation of the polysaccharide [22] was achieved by dissolving 150 mg menCPs in 1 ml of 1 mM sodium periodate solution and mixed in the dark for 30 min at 4³C, 1 ml of ethylene glycol was then added to stop the reaction ; oxidisation with sodium periodate hydrolysed the majority of the polysaccharide (data not shown). To couple the polysaccharide to dFim, this mixture was immediately added to the derivatised protein solution and incubated at 4³C for 2 h. 200 Wl of a freshly prepared sodium borohydride solution (50 mg ml 31 ) was added to the reaction mixture and incubated at 4³C overnight. The product was dialysed (MW cuto¡ 12 000; Sigma) against at least three changes of 5 l of PBS pH 7.4 to remove unconjugated, hydrolysed polysaccharide. The conjugate was puri¢ed and conjugation con¢rmed by size exclusion chromatography (Section 2.3.1).
Protein determination
Protein concentrations were determined using a BCA assay (Pierce).
Polysaccharide determination
Sialic acid concentrations were determined using the Warren assay [24] and total polysaccharide determined by the resorcinol assay [25] .
Immunisations
To determine the immune response to conjugates, groups of ¢ve Balb/c mice (female, 6^9 weeks old) were immunised with two doses of conjugate vaccine containing 10 Wg polysaccharide or unconjugated control antigens; protective e¤cacy was determined after groups of mice received three doses of the above preparations. For assessment of dose response, Balb/c mice (¢ve per group) were immunised with dFim-menCPs(RA) conjugate containing either 0. 96-Well microtitration plates (Immulon) were coated with 1 Wg ml 31 native ¢mbriae, dFim or de-O-acetylated menCPs-methylated human serum albumin (menCPsmHSA) in PBS overnight at 4³C and incubated with serum dilutions. Speci¢c antibodies were detected using goat anti-mouse IgG-HRP and anti-mouse IgM and IgG isotype-HRP conjugates (Jackson) and TMBlue (Universal Biologicals). The antibody titre was de¢ned as the reciprocal of the dilution of serum corresponding to the midpoint of the dose^response curve. This was calculated using interpolation software (Genesis ; Labsystems) on dose^response curves generated from eight dilutions of each serum. Interplate variation was corrected for by using a pool of day 14 sera, and sera showing a titre less than the detection limit were assigned an arbitrary titre of 50 for calculation of geometric means. An avidity ELISA using thiocyanate as the chaotropic agent [26, 27] for anti-menCPs antibodies was carried out on day 35 sera.
Serum bactericidal assay
Serum bactericidal antibodies (SBA) were determined according to standardised methodology [28] using a complement source of 25% baby rabbit complement (Pelfreeze) and N. meningitidis serogroup C strain C11 as the target strain. Titres are expressed as the reciprocal of the ¢nal dilution producing v 50% bactericidal killing after 60 min [29] .
Inhibition assay
Inhibition assays were performed for the detection of polysaccharide-speci¢c antibodies in murine sera 35 days after immunisation with dFim-menCPs(RA) conjugate. Brie£y, dilutions of puri¢ed menCPs (Section 2.1) ranging from 3.9 Wg ml 31 to 500 Wg ml 31 were prepared in a microtitre plate (Sterilin) with PBS, 0.01% (v/v) Tween 20, 10% (v/v) newborn calf serum blocking bu¡er as diluent. Murine sera were diluted 1/100 in blocking bu¡er and an equal volume was added to each well of the microtitre plate containing the polysaccharide. The plate was incubated overnight at 4³C with gentle shaking. Untreated sera were used as a control. Polysaccharide-treated and untreated sera were then assayed by ELISA against menCPs-mHSA. Binding of speci¢c antibody was detected using anti-mouse IgG-HRP (Jackson) and TMBlue (Universal Biologicals). Using the absorbance at 450 nm of the untreated sera as 100% binding, results were expressed as percentage inhibition of antibody binding against concentration of menCPs (Wg ml 31 ) used in the preincubation step with the murine sera. 2.8.1.2. Preparation of inocula. Bacterial inocula were prepared for the infection study by growing B. pertussis on charcoal agar (CA) plates for 48 h at 35³C. Bacteria were then subcultured onto fresh CA plates and incubated for a further 24 h at 35³C. Growth from these plates was dispersed into 10 ml of 1% (w/v) casamino acids to give an OD 550 of approx. 1.0. The suspension was then adjusted in casamino acids to an OD 550 of 0.1, which was estimated to contain approx. 10 8 colony forming units (cfu) ml 31 .
2.8.1.3. Determination of protective e¤cacy. Two weeks after the second dose of antigen, mice were challenged intranasally with B. pertussis. Under light anaesthesia (0.1 ml of Hypnorm/Hypnovel), 50 Wl of bacterial inoculum containing approx. 10 8 cfu ml 31 was administered into the nares and allowed to be inhaled. Seven days post challenge, mice were sacri¢ced by cervical dislocation and lungs and trachea were removed. Each organ was placed into separate glass bottles containing 10 ml of sterile 1% (w/v) casamino acids. The organs were homogenised using a Silverson homogeniser and serial dilutions (10 31 , 10 32 , 10 33 ) of the homogenised tissue were prepared. The numbers of viable bacteria in organs were determined by inoculating 4U25 Wl from each dilution onto selective CA plates containing 40 Wg ml 31 of cephalexin and plates incubated for 6 days at 35³C in an humidi¢ed atmosphere.
Murine intraperitoneal infection model for
N. meningitidis To determine the protective e¤cacy of dFim-menCPs-(RA) conjugate, Balb/c mice (female 6^8 weeks old, Harlan) were immunised on days 1, 21 and 28 with conjugate or an unconjugated mixture of polysaccharide and protein containing 10 Wg ml 31 polysaccharide or dFim. The mice were infected on day 35 using the intraperitoneal (i.p.) infection model [30] . Bacteria were grown in MHB broth for 4 h, adjusted to the required density with the same medium, and mixed with an equal volume of sterile human transferrin (40 mg ml 31 , Sigma) in PBS. Mice received the appropriate challenge dose i.p. in a 0.5 ml suspension and 24 h later a second i.p. injection of 0.2 ml saline containing human transferrin (50 mg ml 31 ) was administered. Susceptibility to infection was monitored for 4 days after infection and the endpoint was reached when mice exhibited symptoms of closed eyes, ru¥ed fur and immobility, at which time mice were euthanatised.
All procedures involving animals were conducted according to the requirements of the UK Home O¤ce Ani- mals (Scienti¢c Procedures) Acts, 1986 and are subject to ethical review.
Results
Puri¢cation of conjugates
Conjugates were puri¢ed by SEC on a Superdex 200 column. Fig. 1A shows the SEC pro¢le for dFim (P2a); some dFim has reassociated and eluted close to the void volume for the column (P1a). The conjugate eluted in the void volume (P1b, Fig. 1B) , while unconjugated dFim and any remaining oligosaccharide eluted in fractions 20^23 (P2b, Fig. 1B) , the pro¢le indicates that the majority of the dFim was conjugated to the menCPs. Immunoblot analysis of SEC fractions using antibody speci¢c for dFim or menCPs was used to con¢rm co-elution of protein and polysaccharide (data not shown). There was some variation in the ratio of polysaccharide:protein in successive preparations of conjugates; dFim-menCPs(RA) conjugate with a polysaccharide :protein ratio of 3.2:1 was used for assessment of the immune response, whereas a conjugate with a polysaccharide:protein ratio of 5.2:1 was used for the determination of protective e¤cacy.
The dFim-menCPs(EDC) conjugate had a polysaccharide:protein ratio of 1:1.75. The menCPs used to produce the conjugate was also analysed by NMR spectroscopy and con¢rmed to be de-O-acetylated (data not shown).
Immune response to conjugates
ELISA
Sera from immunised Balb/c mice were assayed by ELISA to determine the antibody response to native ¢m-briae and menCPs. The antibody titres in Fig. 2 demonstrate a speci¢c, boostable response to menCPs. In mice immunised with d¢m-menCPs(RA), high antibody titres were observed after a boost dose of conjugate and the antibodies were also of high avidity. High serum IgG antibody levels against native ¢mbriae were elicited by all vaccines (Fig. 3) , indicating that ¢mbrial subunit structure is su¤ciently conserved throughout the dissociation and conjugation process to maintain important epitopes. Speci¢c antibodies to dissociated ¢mbriae were observed with all vaccines except menCPs (data not shown).
Isotype ELISA
Immunoglobulin isotype was determined in murine sera after boosting and determined that the response to con- The increase in ratio of IgG:IgM was calculated from the geometric mean ELISA titres of IgG and IgM in pooled murine sera (n = 5). The ratio of IgG:IgM titre in day 35 (post-boost) sera versus the ratio in day 21 (pre-boost) sera was used. jugates was primarily IgG1, indicating a predominantly Th2 response. In addition, the ratio of IgG to IgM was increased following boosting with the conjugate but not with polysaccharide or an unconjugated mixture, indicating that the response to the conjugate is TD, in contrast with the TI response elicited by the polysaccharide and the unconjugated mixture. This observation was noted when sera were assayed against the conjugate or the polysaccharide (Table 1 and Table 2 , respectively). The greatest increase in ratio was observed in the dFim-menCPs(RA) conjugate sera.
Dose response
Sera from Balb/c mice immunised with dFim-menCPs-(RA) conjugate containing either 0.1 Wg, 1.0 Wg or 10 Wg Ps were assayed by ELISA to determine the IgG response to menCPs and native ¢mbriae. A dose^response e¡ect was observed for both antigens. A boostable response was observed against menCPs at both 1 Wg and 10 Wg Ps, with the greatest response in mice given 10 Wg menCPs in the conjugate dose. However, a boostable anti-¢mbriae response was observed only at the higher dose (Fig. 4). 
Serum bactericidal assay
Bactericidal antibody titres were determined in the sera of immunised mice after boosting. The highest serum bactericidal response was found in mice immunised with d¢m-menCPs(RA) conjugate. After three doses of this conjugate, the serum bactericidal titre increased to 1/2048 (Fig.  5 ).
Inhibition ELISA
In the inhibition ELISA, 200 Wg ml 31 menCPs was suf¢cient to produce s 90% inhibition of binding of the conjugate antibody to conjugate bound to the assay plate (Fig. 6 ). These results demonstrate that immunisation with dFim-menCPs(RA) conjugate elicits polysaccharidespeci¢c antibody. 
Protective e¤cacy of dFim-menC conjugate
The dFim-menCPs(RA) gave the highest avidity and serum bactericidal antibodies and was therefore used to immunise mice in a murine i.p. challenge model of meningococcal disease (Section 2.6). Mice were immunised with either conjugate, menCPs alone or dFim and challenged with the homologous serogroup C strain using two challenge doses. The infection was monitored over a period of 4 days (Fig. 7) . The dFim-menCPs conjugate a¡orded 100% protection at both challenge doses compared with menCPs alone which gave 100% protection at the low dose 8 cfu (n = 5). At both challenge doses, the di¡er-ence in protection between mice immunised with conjugate and unvaccinated controls was signi¢cant (P90.01). Fig. 6 . Inhibition ELISA of D35 murine sera after three doses of dFimmenCPs(RA) conjugate. The sera from ¢ve female Balb/c mice were pooled prior to the inhibition assay. Fig. 5 . Serum bactericidal antibody titre in murine sera comparing conjugates prepared using di¡erent chemistries. SBA titre was determined in pooled murine sera (n = 5). The SBA titre is expressed as the geometric mean of duplicate serum bactericidal assays. but no protection at the higher dose of 7.5U10 8 cfu. For mice immunised with conjugate, the di¡erence in protection when compared with the unvaccinated controls was signi¢cant at both challenge doses (P 9 0.01, Finney contingency tables).
Protective e¤cacy of dFim
The ability of dissociated ¢mbriae to protect mice against intranasal colonisation with B. pertussis was determined. Unimmunised animals were more susceptible to infection with B. pertussis, whereas all animals immunised with either native or dissociated ¢mbriae were protected (Fig. 8) . Although there was some variability in the levels of colonisation of lungs and trachea, particularly in the unvaccinated group, protection was observed and dissociated ¢mbriae induced similar protection against respiratory colonisation to that induced by immunisation with native ¢mbriae.
Discussion
Enhancement of the immunogenicity of polysaccharides by coupling polysaccharides or oligosaccharides to proteins is well established [31^33]. Typically, polysaccharides have been coupled to large immunogenic proteins such as TT or DT. These proteins were chosen in most cases because both have been used for human vaccination for many years without widely reported adverse side e¡ects. However, since most individuals are immunised with TT and DT, the response against an antigen coupled to these carriers may be inhibited by anti-carrier immunity. This immunomodulatory e¡ect is termed carrier-induced epitopic suppression [34] and has been demonstrated with a number of synthetic peptide-protein conjugates using TT as the carrier protein [35^37]. For example, Peeters et al. [38] observed that when mice were primed with a high dose of carrier protein (25 Wg) before immunisation with polysaccharide-protein conjugates, the anti-polysaccharide antibody was suppressed. They also found that the consequences of carrier priming persisted after repeated immunisations with the conjugate vaccine and occurred with both high molecular mass polysaccharides and oligosaccharides. This indicates that high dose carrier priming may cause signi¢cant suppression of the anti-polysaccharide IgG antibody response induced by protein-polysaccharide conjugates. Although the mechanism of this suppression is unclear, involvement of T suppressor cells and carrier-speci¢c B memory cells has been reported [38] . Therefore, if more than one conjugate vaccine is used, or if they are given as multivalent formulations with the same carrier protein, the likelihood of carrier-induced epitopic suppression is increased. The immunological history of the vaccinee would also be important [39] . Therefore, there is a need for alternative carrier proteins for use in conjugate vaccines.
B. pertussis components in a vaccine may modulate immune suppression and administration of pertussis vaccine or puri¢ed components has been found to block the establishment of epitopic suppression. Administration of B. pertussis components enhanced antibody responses to both carrier and synthetic peptides [36] . In this study, immunisation of mice with dissociated ¢mbriae demonstrated a protective e¡ect in an intranasal colonisation model for B. pertussis infection. Dissociated ¢mbriae were used as carrier proteins for menCPs because native ¢mbriae conjugates were di¤cult to characterise, principally due to their large molecular mass and tendency to aggregate [16] . By using dFim, the conjugation process proved to be more e¤cient and it was possible to detect the increase in molecular mass when conjugated to menCPs. Native, unhydrolysed menCPS was used as the starting material as previous studies have demonstrated a direct relationship between the molecular size of a polysaccharide and its ability to induce an immune response in man [2] .
Rubenstein and Stein [40] reported that the immune response to menCPs in Balb/c mice provides a model system which closely parallels the response in humans. Conjugating dFim to menCPs by reductive amination resulted in a conjugate that produced high, boostable IgG responses in our Balb/c mouse model. This was not observed when mice were immunised with menCPs alone or an unconjugated mixture of dFim and menCPs. Responses to a conjugate produced by carbodiimide coupling were less pronounced; the reasons for this are unclear, but may be due to the lower polysaccharide :protein ratio in this conjugate or contaminating unconjugated unhydrolysed menCPs which was not removed by dialysis. The responses were TD, as demonstrated by an increase in the IgG:IgM ratio after boosting. The antibodies were of high avidity and speci¢c for the polysaccharide moiety; in addition, antibodies were found to be bactericidal against a heterologous serogroup C strain. The conjugate provided 100% protection in mice against challenge with 7.5U10 8 cfu of the homologous meningococcal strain.
Conjugates of menCPs and TT using long chain saccharides or short chain oligosaccharides conjugated by reductive amination [6, 33, 41] have been used in previous studies to immunise Balb/c mice. These studies showed that the conjugate, compared with unconjugated menCPs, resulted in an isotype shift from predominantly IgM and IgG3 to predominantly IgG1, accompanied by a large (10-fold) increase in bactericidal activity and an increase in antibody a¤nity. Fukasawa et al. [42] conjugated menCPs to N. meningitidis serogroup B outer membrane vesicles by carbodiimide coupling using ADH as a C6 spacer. They studied the immune response in C3H/Hepas mice and found that this conjugate elicited boostable IgG titres and bactericidal antibodies. The bactericidal antibody response was increased approx. 2-fold when comparing sera raised against menCPs alone and the conjugate vaccine. These responses are similar to those observed in this study where a v 10-fold increase in bactericidal titre was seen with the reductive amination conjugate, but a much smaller increase in titre with the conjugate produced by carbodiimide coupling. It is, however, di¤cult to make comparisons with the study of Fukasawa et al. [42] because a di¡erent mouse strain was used.
This study indicates that immunisation with a dFimmenCPs conjugate vaccine is protective in animal models and elicits speci¢c and functional TD antibody responses. Therefore, this vaccine should protect against serogroup C meningococcal disease and augment protection against pertussis when acellular vaccines de¢cient in ¢mbriae are used. Furthermore, it has been recommended that acellular pertussis vaccine should be given to adults in order to maintain life-long protection [43] . Therefore, a conjugate vaccine based upon B. pertussis ¢mbriae and menCPs, which could be given to young adults as well as infants to protect against meningococcal disease and pertussis, would have clear advantages.
